Straits Times Index
3,304.41 -17.67 (-0.53%) Nikkei
39,134.79 +96.63 (+0.25%) Hang Seng
18,174.18 -192.77 (-1.05%) FTSE 100
8,244.69 +16.21 (+0.20%) Bitcoin USD
67,774.42 -1,633.19 (-2.35%) CMC Crypto 200
1,402.70 -38.93 (-2.70%)
AKRO Jan 2026 12.500 put
| Previous close | 2.2000 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 4.8000 |
| Strike | 12.50 |
| Expiry date | 2026-01-16 |
| Day's range | 2.2000 - 2.2000 |
| Contract range | N/A |
| Volume | |
| Open interest | 5 |
GlobeNewswireAkero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024
SOUTH SAN FRANCISCO, Calif., June 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with serious metabolic disorders marked by high unmet medical need, today announced two presentations featuring its lead product candidate efruxifermin (EFX) at the European Association for the Study of the Liver (EASL) Congress 2024, in Milan, Italy. The presentations will also be available on Akero’s w
ZacksViking (VKTX) Falls 10% Despite Upbeat NASH Study Results
Viking Therapeutics (VKTX) reports promising 52-week treatment data from a mid-stage study on its experimental NASH drug. However, shares drop as management did not provide any info on future plans.
- GlobeNewswire
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 4:00 p.m. E.T. in New York, NY. A live webcast of the Company presentation will be available through the investor relations section
